Glenmark Pharma launches nasal spray for treatment of Covid patients in India

Glenmark Pharma launches Nitric Oxide Nasal Spray (FabiSpray) in India for the treatment of adult patients with Covid-19 in partnership with SaNOtize

Livemint
Published9 Feb 2022, 09:05 AM IST
Picture for represenatation. FabiSpray, Nitric Oxide Nasal Spray, is designed to kill the COVID-19 virus in the upper airways
Picture for represenatation. FabiSpray, Nitric Oxide Nasal Spray, is designed to kill the COVID-19 virus in the upper airways(AFP)

Glenmark Pharmaceuticals Limited (Glenmark) and Canadian pharmaceutical company SaNOtize Research & Development Corp. today announced the launch of its Nitric Oxide Nasal Spray under the brand name FabiSpray in India for the treatment of adult patients with COVID-19 who have high risk of progression of the disease. 

Glenmark earlier received manufacturing and marketing approval from the Drugs Controller General of India (DCGI) for NONS as part of the accelerated approval process.

“As a leading pharmaceutical player, it is important that we are an integral part of India’s fight against the COVID-19 pandemic. We are happy to receive regulatory approval for Nitric Oxide Nasal Spray (FabiSpray®) and launch it in partnership with SaNOtize. This reaffirms our commitment to providing yet another safe and effective antiviral treatment for COVID-19, and we are confident it will offer patients a much needed and timely therapy option,”Robert Crockart, Chief Commercial Officer, Glenmark Pharmaceuticals Ltd. said.

What is FabiSpray

FabiSpray, Nitric Oxide Nasal Spray, is designed to kill the COVID-19 virus in the upper airways. It has proven anti-microbial properties with a direct virucidal effect on SARS-CoV-2. NONS when sprayed over nasal mucosa acts as a physical and chemical barrier against the virus, preventing it from incubating and spreading to the lungs.

Indian Phase 3 Clinical Trial Outcomes

A Phase 3 clinical trial was conducted in adult COVID-19 patients across 20 clinical sites in India. The double-blind, parallel-arm, multicenter study, conducted in 306 patients evaluated the efficacy and safety of Nitric.

Dr. Monika Tandon, Senior VP & Head - Clinical Development, Glenmark Pharmaceuticals Ltd., commented: “The results from this Phase 3, double-blind, placebo-controlled trial are encouraging. Demonstration of reduction in the viral load has a significant positive impact from a patient and community perspective. In the current scenario, with new emerging variants exhibiting high transmissibility, NONS provides a useful option in India’s fight against COVID-19.”

Dr. Srikanth Krishnamurthy one of the Principal Investigators of the study commented, “I have had a chance to view the results of the study. Nitric Oxide Nasal Spray lowers the viral load and hastens RT-PCR negativity when used early in COVID 19 infection leading to recovery. Most importantly, viral load reduction with NONS has the potential to reduce the chain of transmission. Last but not the least, NONS being topical, is safe, and makes this therapeutic option very attractive”.

 

 

Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.

MoreLess
First Published:9 Feb 2022, 09:05 AM IST
Business NewsScienceGlenmark Pharma launches nasal spray for treatment of Covid patients in India

Get Instant Loan up to ₹10 Lakh!

  • Employment Type

    Most Active Stocks

    Tata Steel share price

    150.40
    10:17 AM | 8 NOV 2024
    -0.5 (-0.33%)

    Indian Hotels Company share price

    716.60
    10:17 AM | 8 NOV 2024
    33 (4.83%)

    Tata Motors share price

    814.80
    10:17 AM | 8 NOV 2024
    -5 (-0.61%)

    Indian Oil Corporation share price

    142.00
    10:17 AM | 8 NOV 2024
    -2.2 (-1.53%)
    More Active Stocks

    Market Snapshot

    • Top Gainers
    • Top Losers
    • 52 Week High

    Indian Hotels Company share price

    716.00
    10:16 AM | 8 NOV 2024
    32.4 (4.74%)

    Page Industries share price

    47,030.00
    10:16 AM | 8 NOV 2024
    1924.5 (4.27%)

    National Aluminium Company share price

    246.30
    10:16 AM | 8 NOV 2024
    7.75 (3.25%)

    Apollo Hospitals Enterprise share price

    7,472.00
    10:15 AM | 8 NOV 2024
    47.4 (0.64%)
    More from 52 Week High

    Great Eastern Shipping Company share price

    1,206.00
    10:16 AM | 8 NOV 2024
    -84.95 (-6.58%)

    GMM Pfaudler share price

    1,287.55
    10:13 AM | 8 NOV 2024
    -87.35 (-6.35%)

    Rail Vikas Nigam share price

    452.80
    10:16 AM | 8 NOV 2024
    -24.75 (-5.18%)

    IRCON International share price

    204.50
    10:16 AM | 8 NOV 2024
    -10.6 (-4.93%)
    More from Top Losers

    ITI share price

    287.15
    10:16 AM | 8 NOV 2024
    20.5 (7.69%)

    Motilal Oswal Financial Services share price

    996.70
    10:16 AM | 8 NOV 2024
    62.5 (6.69%)

    Tejas Networks share price

    1,438.15
    10:16 AM | 8 NOV 2024
    70.15 (5.13%)

    Indian Hotels Company share price

    716.00
    10:16 AM | 8 NOV 2024
    32.4 (4.74%)
    More from Top Gainers

    Recommended For You

      More Recommendations

      Gold Prices

      • 24K
      • 22K
      Bangalore
      78,575.000.00
      Chennai
      78,581.000.00
      Delhi
      78,733.000.00
      Kolkata
      78,585.000.00

      Fuel Price

      • Petrol
      • Diesel
      Bangalore
      102.92/L0.00
      Chennai
      100.80/L0.00
      Kolkata
      104.95/L0.00
      New Delhi
      94.77/L0.00

      Popular in Science

        HomeMarketsPremiumInstant LoanMint Shorts